The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells

Journal of Biological Chemistry

Volumn 288, Issue 16, 2013, Pages 11047-11065

  Patki, Mugdha ^a,b   Chari, Venkatesh ^a,b   Sivakumaran, Suneethi ^b   Gonit, Mesfin ^b,c   Trumbly, Robert ^b   Ratnam, Manohar ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTORS; CRITICAL COMPONENT; DOMAIN TRANSCRIPTION; DRUG TARGETS; PROSTATE CANCER CELLS; PROSTATE TUMOR;

CELLS; TRANSCRIPTION FACTORS; TUMORS;

DISEASES;

ANDROGEN RECEPTOR; PROTEIN C FOS; TRANSCRIPTION FACTOR EGR 1; TRANSCRIPTION FACTOR ELK 1;

ADOLESCENT; ADULT; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE PROGRESSION; CELL NUCLEUS; CONTROLLED STUDY; DRUG TARGETING; GENE INDUCTION; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; MALE; MITOSIS; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ADOLESCENT; ADULT; ANDROGEN ANTAGONISTS; ANILIDES; CELL NUCLEUS; ETS-DOMAIN PROTEIN ELK-1; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MALE; NITRILES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TOSYL COMPOUNDS;

EID: 84876546233     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.438473     Document Type: Article

References (54)

1. Ruizeveld de Winter, J. A., Janssen, P. J., Sleddens, H. M., Verleun-Mooijman, M. C., Trapman, J., Brinkmann, A. O., Santerse, A. B., Schröder, F. H., and van der Kwast, T. H. (1994) Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am. J. Pathol. 144, 735-746.
2. Linja, M. J., Savinainen, K. J., Saramäki, O. R., Tammela, T. L., Vessella, R. L., and Visakorpi, T. (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61, 3550-3555.
3. Zegarra-Moro, O. L., Schmidt, L. J., Huang, H., and Tindall, D. J. (2002) Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 62, 1008-1013.
4. Li, T. H., Zhao, H., Peng, Y., Beliakoff, J., Brooks, J. D., and Sun, Z. (2007) A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res. 35, 2767-2776.
5. Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., and Sawyers, C. L. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39.
6. Miyamoto, H., Messing, E. M., and Chang, C. (2004) Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 61, 332-353.
7. Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., Kung, H. J., Brodie, A. M., Edwards, J., and Qiu, Y. (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69, 2305-2313.
8. Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., Bova, G. S., and Luo, J. (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16-22.
9. Gonit, M., Zhang, J., Salazar, M. d., Cui, H., Shatnawi, A., Trumbly, R., and Ratnam, M. (2011) Hormone depletion-insensitivity of prostate cancer cells is supported by the AR without binding to classical response elements. Mol. Endocrinol. 25, 621-634.
10. Cai, C., Chen, S., Ng, P., Bubley, G. J., Nelson, P. S., Mostaghel, E. A., Marck, B., Matsumoto, A. M., Simon, N. I., Wang, H., Chen, S., and Balk, S. P. (2011) Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 71, 6503-6513.
11. Larsson, R., Mongan, N. P., Johansson, M., Shcherbina, L., Abrahamsson, P. A., Gudas, L. J., Sterner, O., and Persson, J. L. (2011) Clinical trial update and novel therapeutic approaches for metastatic prostate cancer. Curr. Med. Chem. 18, 4440-4453.
12. Holzbeierlein, J. M., McLaughlin, M. D., and Thrasher, J. B. (2004) Complications of androgen deprivation therapy for prostate cancer. Curr. Opin. Urol. 14, 177-183.
13. Pratt, W. B., and Toft, D. O. (1997) Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev. 18, 306-360.
14. Beato, M., Herrlich, P., and Schütz, G. (1995) Steroid hormone receptors: many actors in search of a plot. Cell 83, 851-857.
15. Glass, C. K., and Rosenfeld, M. G. (2000) The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14, 121-141.
16. McKenna, N. J., and O'Malley, B. W. (2002) Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108, 465-474.
17. Shaffer, P. L., Jivan, A., Dollins, D. E., Claessens, F., and Gewirth, D. T. (2004) Structural basis of androgen receptor binding to selective androgen response elements. Proc. Natl. Acad. Sci. U.S.A. 101, 4758-4763.
18. Gioeli, D., Wunderlich, W., Sebolt-Leopold, J., Bekiranov, S., Wulfkuhle, J. D., Petricoin, E. F., 3rd, Conaway, M., and Weber, M. J. (2011) Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer. Mol. Cancer Ther. 10, 1581-1590.
19. Chen, S., Xu, Y., Yuan, X., Bubley, G. J., and Balk, S. P. (2006) Androgen receptor phosphorylation and stabilization in prostate cancer by cyclindependent kinase 1. Proc. Natl. Acad. Sci. U.S.A. 103, 15969-15974.
20. Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., Wu, T., Regan, M. M., Meyer, C. A., Carroll, J. S., Manrai, A. K., Jänne, O. A., Balk, S. P., Mehra, R., Han, B., Chinnaiyan, A. M., Rubin, M. A., True, L., Fiorentino, M., Fiore, C., Loda, M., Kantoff, P. W., Liu, X. S., and Brown, M. (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138, 245-256.
21. Zhang, J., Gonit, M., Salazar, M. D., Shatnawi, A., Shemshedini, L., Trumbly, R., and Ratnam, M. (2010) C/EBPα redirects androgen receptor signaling through a unique bimodal interaction. Oncogene 29, 723-738.
22. Mukhopadhyay, N. K., Ferdinand, A. S., Mukhopadhyay, L., Cinar, B., Lutchman, M., Richie, J. P., Freeman, M. R., and Liu, B. C. (2006) Unraveling androgen receptor interactomes by an array-based method: discovery of proto-oncoprotein c-Rel as a negative regulator of androgen receptor. Exp. Cell Res. 312, 3782-3795.
23. Hollenhorst, P. C., Shah, A. A., Hopkins, C., and Graves, B. J. (2007) Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev. 21, 1882-1894.
24. Wei, G. H., Badis, G., Berger, M. F., Kivioja, T., Palin, K., Enge, M., Bonke, M., Jolma, A., Varjosalo, M., Gehrke, A. R., Yan, J., Talukder, S., Turunen, M., Taipale, M., Stunnenberg, H. G., Ukkonen, E., Hughes, T. R., Bulyk, M. L., and Taipale, J. (2010) Genome-wide analysis of ETS-family DNAbinding in vitro and in vivo. EMBO J. 29, 2147-2160.
25. Sharrocks, A. D. (2002) Complexities in ETS-domain transcription factor function and regulation: lessons from the TCF (ternary complex factor) subfamily. The Colworth Medal Lecture. Biochem. Soc. Trans. 30, 1-9.
26. Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., Lander, E. S., Loda, M., Kantoff, P. W., Golub, T. R., and Sellers, W. R. (2002) Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1, 203-209.
27. Yordy, J. S., and Muise-Helmericks, R. C. (2000) Signal transduction and the Ets family of transcription factors. Oncogene 19, 6503-6513.
28. Yang, S. H., Jaffray, E., Hay, R. T., and Sharrocks, A. D. (2003) Dynamic interplay of the SUMO and ERK pathways in regulating Elk-1 transcriptional activity. Mol. Cell 12, 63-74.
29. Boros, J., Donaldson, I. J., O'Donnell, A., Odrowaz, Z. A., Zeef, L., Lupien, M., Meyer, C. A., Liu, X. S., Brown, M., and Sharrocks, A. D. (2009) Elucidation of the ELK1 target gene network reveals a role in the coordinate regulation of core components of the gene regulation machinery. Genome Res. 19, 1963-1973.
30. Cesari, F., Rennekampff, V., Vintersten, K., Vuong, L. G., Seibler, J., Bode, J., Wiebel, F. F., and Nordheim, A. (2004) Elk-1 knock-out mice engineered by Flp recombinase-mediated cassette exchange. Genesis 38, 87-92.
31. Best, C. J., Gillespie, J. W., Yi, Y., Chandramouli, G. V., Perlmutter, M. A., Gathright, Y., Erickson, H. S., Georgevich, L., Tangrea, M. A., Duray, P. H., González, S., Velasco, A., Linehan, W. M., Matusik, R. J., Price, D. K., Figg, W. D., Emmert-Buck, M. R., and Chuaqui, R. F. (2005) Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin. Cancer Res. 11, 6823-6834.
32. Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57.
33. Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1-13.
34. Wu, H. C., Hsieh, J. T., Gleave, M. E., Brown, N. M., Pathak, S., and Chung, L. W. (1994) Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int. J. Cancer 57, 406-412.
35. Massie, C. E., Lynch, A., Ramos-Montoya, A., Boren, J., Stark, R., Fazli, L., Warren, A., Scott, H., Madhu, B., Sharma, N., Bon, H., Zecchini, V., Smith, D. M., Denicola, G. M., Mathews, N., Osborne, M., Hadfield, J., Macarthur, S., Adryan, B., Lyons, S. K., Brindle, K. M., Griffiths, J., Gleave, M. E., Rennie, P. S., Neal, D. E., and Mills, I. G. (2011) The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 30, 2719-2733.
36. Hayward, S. W., and Cunha, G. R. (2000) The prostate: development and physiology. Radiol. Clin. North Am. 38, 1-14.
37. Safe, S., and Kim, K. (2004) Nuclear receptor-mediated transactivation through interaction with Sp proteins. Prog. Nucleic Acid Res. Mol. Biol. 77, 1-36.
38. Safe, S., and Kim, K. (2008) Non-classical genomic estrogen receptor (ER)/ specificity protein and ER/activating protein-1 signaling pathways. J. Mol. Endocrinol. 41, 263-275.
39. Besnard, A., Galan-Rodriguez, B., Vanhoutte, P., and Caboche, J. (2011) Elk-1 a transcription factor with multiple facets in the brain. Front. Neurosci. 5, 35.
40. Yang, S. H., and Sharrocks, A. D. (2005) PIASx acts as an Elk-1 coactivator by facilitating derepression. EMBO J. 24, 2161-2171.
41. Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X. W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J. E., Shah, R. B., Pienta, K. J., Rubin, M. A., and Chinnaiyan, A. M. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648.
42. Tomlins, S. A., Mehra, R., Rhodes, D. R., Smith, L. R., Roulston, D., Helgeson, B. E., Cao, X., Wei, J. T., Rubin, M. A., Shah, R. B., and Chinnaiyan, A. M. (2006) TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66, 3396-3400.
43. Helgeson, B. E., Tomlins, S. A., Shah, N., Laxman, B., Cao, Q., Prensner, J. R., Cao, X., Singla, N., Montie, J. E., Varambally, S., Mehra, R., and Chinnaiyan, A. M. (2008) Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 68, 73-80.
44. Yu, J., Yu, J., Mani, R. S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., Gong, Y., Cheng, H., Laxman, B., Vellaichamy, A., Shankar, S., Li, Y., Dhanasekaran, S. M., Morey, R., Barrette, T., Lonigro, R. J., Tomlins, S. A., Varambally, S., Qin, Z. S., and Chinnaiyan, A. M. (2010) An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17, 443-454.
45. Shin, S., Kim, T. D., Jin, F., van Deursen, J. M., Dehm, S. M., Tindall, D. J., Grande, J. P., Munz, J. M., Vasmatzis, G., and Janknecht, R. (2009) Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res. 69, 8102-8110.
46. Massie, C. E., Adryan, B., Barbosa-Morais, N. L., Lynch, A. G., Tran, M. G., Neal, D. E., and Mills, I. G. (2007) New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep. 8, 871-878.
47. Duan, R., Xie, W., Burghardt, R. C., and Safe, S. (2001) Estrogen receptormediated activation of the serum response element in MCF-7 cells through MAPK-dependent phosphorylation of Elk-1. J. Biol. Chem. 276, 11590-11598.
48. Duan, R., Xie, W., Li, X., McDougal, A., and Safe, S. (2002) Estrogen regulation of c-fos gene expression through phosphatidylinositol-3- kinasedependent activation of serum response factor in MCF-7 breast cancer cells. Biochem. Biophys. Res. Commun. 294, 384-394.
49. Shore, P., Whitmarsh, A. J., Bhaskaran, R., Davis, R. J., Waltho, J. P., and Sharrocks, A. D. (1996) Determinants of DNA-binding specificity of ETSdomain transcription factors. Mol. Cell. Biol. 16, 3338-3349.
50. Norris, J. D., Chang, C. Y., Wittmann, B. M., Kunder, R. S., Cui, H., Fan, D., Joseph, J. D., and McDonnell, D. P. (2009) The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol. Cell 36, 405-416.
51. Zhang, J., Wilkinson, J. E., Gonit, M., Keck, R., Selman, S., and Ratnam, M. (2008) Expression and sub-cellular localization of the CCAAT/enhancer binding protein α in relation to postnatal development and malignancy of the prostate. Prostate 68, 1206-1214.
52. Urbanucci, A., Sahu, B., Seppälä, J., Larjo, A., Latonen, L. M., Waltering, K. K., Tammela, T. L., Vessella, R. L., Lähdesmäki, H., Jänne, O. A., and Visakorpi, T. (2012) Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene 31, 2153-2163.
53. Chng, K. R., Chang, C. W., Tan, S. K., Yang, C., Hong, S. Z., Sng, N. Y., and Cheung, E. (2012) A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J. 31, 2810-2823.
54. Tan, P. Y., Chang, C. W., Chng, K. R., Wansa, K. D., Sung, W. K., and Cheung, E. (2012) Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. Mol. Cell. Biol. 32, 399-414.